RMD -4.22%: At a conference overnight, the CEO of RMD Rob Douglas has painted a fairly challenging picture around supply chains, more or less reiterating what F&P Healthcare (FPH) said yesterday. He said rising freight costs and semiconductor chip shortages are curbing its ability to meet surging global demand for its devices. Rob went onto say that RMD was seeing almost “unlimited demand” for its products as a major recall from its competitor Philips continues, but they are having trouble keeping up. “We’re pulling out all stops there as to what we can. But unfortunately, there still will be a shortfall of treatment,” Mr Douglas said. To put some numbers around this, US based research house KebBanc now think it will be very challenging for RMD to reach the expected $300-350m benefit from the recall. Resmed was down ~8% overnight and opened sharply lower this morning before partially recovering.
We remain long RMD in our Flagship Growth Portfolio
Add To Hit List
